View Future GrowthOrganoClick 過去の業績過去 基準チェック /06OrganoClickは5.8%の年平均成長率で業績を伸ばしているが、Chemicals業界はdecliningで4.4%毎年増加している。売上は成長しており、年平均1.4%の割合である。主要情報5.79%収益成長率7.28%EPS成長率Chemicals 業界の成長12.41%収益成長率1.35%株主資本利益率-192.32%ネット・マージン-35.17%次回の業績アップデート17 Jul 2026最近の業績更新お知らせ • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026お知らせ • Feb 13OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025お知らせ • Dec 03+ 3 more updatesOrganoClick AB (publ) to Report Q1, 2025 Results on May 06, 2025OrganoClick AB (publ) announced that they will report Q1, 2025 results on May 06, 2025Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.047 loss per share (vs kr0.042 loss in 3Q 2023)Third quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 22Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023)Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • May 02First quarter 2024 earnings released: kr0.022 loss per share (vs kr0.01 loss in 1Q 2023)First quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 24OrganoClick AB (publ), Annual General Meeting, May 26, 2026OrganoClick AB (publ), Annual General Meeting, May 26, 2026, at 16:00 W. Europe Standard Time. Location: organoclick`s head office at linjalvagen 9 in taby, Swedenお知らせ • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026お知らせ • Jul 18OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million.OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million. Security Name: Shares Security Type: Common Stock Securities Offered: 11,543,290 Price\Range: SEK 1.76 Transaction Features: Rights Offeringお知らせ • May 20OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) announced at the AGM held on May 20, 2025, approved Johan Magnusson was elected as Chairman of the Board. The Board also gave a big thank to the outgoing Chairman of the board Jan Johansson for his contribution to the board and the company during his 9 years as Chairman of the board.お知らせ • Apr 16OrganoClick AB (publ), Annual General Meeting, May 20, 2025OrganoClick AB (publ), Annual General Meeting, May 20, 2025, at 13:00 W. Europe Standard Time. Location: at convendum, brahegatan 10, stockholm Swedenお知らせ • Feb 13OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025お知らせ • Dec 03+ 3 more updatesOrganoClick AB (publ) to Report Q1, 2025 Results on May 06, 2025OrganoClick AB (publ) announced that they will report Q1, 2025 results on May 06, 2025Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.047 loss per share (vs kr0.042 loss in 3Q 2023)Third quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.New Risk • Nov 06New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (€24.4m market cap, or US$26.2m).New Risk • Oct 29New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€25.0m market cap, or US$27.0m).Reported Earnings • Jul 22Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023)Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Jun 15OrganoClick AB (publ) Announces CFO ChangesOrganoClick AB (publ) has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClick's finance and economics department and be part of the group's management team. Carin has more than 20 years of experience from various finance functions from, among others, Bristol Myers Squibb group, ByggFakta group and Team Olivia group. Carin has a M. Sc. in Economics with a specialization in financial mathematics at Karlstad University. For more than 25 years, Carin has worked in finance departments at both manufacturing companies and service companies, in both smaller companies and large groups. Previous experiences include roles as CFO for Olivia Hemomsorg, Finance manager for the medical technology company Convatec (part of the Bristol Myers Squibb Group), Head of Business Control Nordic region at ByggFakta Group and as Strategic Controller at the kitchen manufacturer Nobia. Carin takes over as CFO on July 15, and as previously announced, OrganoClick's current CFO Jessica Sundborg will leave the company 21 of August.New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€27.7m market cap, or US$30.1m).お知らせ • May 16OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) at its Annual General Meeting held on 15 May 2024 approved the election of Johan Magnusson as board member. The Board also gave a big thank to the outgoing board member Malin Bugge for her contribution to the board and the company during her 4 years as a board member.Reported Earnings • May 02First quarter 2024 earnings released: kr0.022 loss per share (vs kr0.01 loss in 1Q 2023)First quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.New Risk • Apr 30New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (€25.4m market cap, or US$27.3m).お知らせ • Apr 23OrganoWood AB (publ) Announces Three-Year Results from the Field Study EN 12037 for Organowood NowaOrganowood Nowa is currently subjected to one of the toughest standard field tests available for wood above ground, EN 12037! The test runs for 5 years in Malaysia and Denmark and now publish the three-year results. The independent external institute Dansk Teknologisk Institut therefore carries out the EN 12037 field test with Organowood Nowa in both Denmark and Malaysia. The references, which consist of untreated pine wood and the wood impregnated with CCA (chromium, copper and arenic), which has been banned for 20 years, were also included in the test. The scale for assessing degradation ranges from grade 0-4, where 0 meas that the wood is unaffected and 4 means that the wood is completely degraded. The untreated reference in Malaysia was completely degraded after 3 years, by rot fungus but also in some cases by termites. Pine pressure-impregnated with CCA was, as expected, unaffected. But also OrganoWood Nowa was completely unaffected with grade 0 on the scale! The result shows a very good wood protection even in the warm and humid environment that a rainforest offers. The field study will continue and will continuously report results from both Denmark and Malaysia.お知らせ • Apr 19Jessica Sundborg to Leave as CFO of OrganoClick AB (publ)OrganoClick AB (publ) announced that its CFO since 2013, Jessica Sundborg is leaving her position to move on to a new position outside the company. Jessica will remain as CFO until she leaves her position after the summer. The work to recruit a successor has begun.New Risk • Apr 17New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (€26.5m market cap, or US$28.2m).お知らせ • Apr 11Organoclick AB (Publ) Announces That Malin Bugge, Board Member, Has Declined Re-ElectionOrganoClick AB (publ) announced that Malin Bugge, who has been a board member since 2020, has declined re-election.Reported Earnings • Apr 08Full year 2023 earnings released: kr0.16 loss per share (vs kr0.45 loss in FY 2022)Full year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 23OrganoClick and PulPac Launches Plastic-Free Coffee Lid Reducing Co2 Footprint with 80%OrganoClick and PulPac has collaborated for several years in developing 100% biobased and biodegradable dry-molded products. By combining PulPac's dry molded fiber technology with OrganoClick's biobased and biodegradable binders, a biobased high-performing coffee lid, compliant with paper recycling have been developed. The innovative coffee lid is now launched for the take away market. PulPac's technology in combination with OrganoClick's biobased binders sets a new standard for high performing and sustainable packaging. It requires less energy and water than the traditional method, resulting in a reduced carbon footprint with up to 80% compared to traditional alternatives. One of the first products out is a plastic-free coffee lid which align with the recent EU legislation for take away product. Annual global consumption of coffee lids is estimated at 100,000,000,000 and with the new coffee lid, the CO2 footprint is reduced with up to 80%. The coffee lid is made green inside with the support of OrganoClick's biobased, biodegradable and home compostable binder, in part manufactured from waste streams from the food industry. The use of OrganoClick's binder resulting in a paper lid with much higher performance. The objectives are also to replace as much as possible of traditional plastic lids available on the market, thereby reducing the risk for microplastics ending up in the environment.Reported Earnings • Feb 16Full year 2023 earnings released: kr0.16 loss per share (vs kr0.45 loss in FY 2022)Full year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.お知らせ • Dec 20OrganoClick AB (publ), Annual General Meeting, May 15, 2024OrganoClick AB (publ), Annual General Meeting, May 15, 2024.お知らせ • Dec 19+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 results on Feb 13, 2025Reported Earnings • Nov 10Third quarter 2023 earnings released: kr0.042 loss per share (vs kr0.093 loss in 3Q 2022)Third quarter 2023 results: kr0.042 loss per share (improved from kr0.093 loss in 3Q 2022). Revenue: kr33.4m (up 50% from 3Q 2022). Net loss: kr4.13m (loss narrowed 55% from 3Q 2022). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany.New Risk • Nov 10New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€26.4m market cap, or US$28.2m).New Risk • Nov 04New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€28.3m market cap, or US$30.3m).Breakeven Date Change • Nov 03Forecast to breakeven in 2025The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.90m in 2025. Average annual earnings growth of 107% is required to achieve expected profit on schedule.お知らせ • Oct 17OrganoClick AB (publ) Announces Nomination CommitteeOrganoClick AB (publ) announced composition of nomination committee. It is composed of Peter Lindell, representing Cidro Förvaltning and himself, Håkan Gustavson representing Beijer Ventures, the Beijer foundations, and himself, and Mårten Hellberg, representing M. Hellberg AB and himself. Peter Lindell was appointed as Chairman of the Nomination committee as the individually largest shareholder in OrganoClick AB.Reported Earnings • Aug 18Second quarter 2023 earnings released: kr0.03 loss per share (vs kr0.09 loss in 2Q 2022)Second quarter 2023 results: kr0.03 loss per share (improved from kr0.09 loss in 2Q 2022). Revenue: kr41.0m (up 6.5% from 2Q 2022). Net loss: kr2.67m (loss narrowed 70% from 2Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.New Risk • Jul 19New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr40m Forecast net loss in 2 years: kr1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr31m). Currently unprofitable and not forecast to become profitable over next 2 years (kr1.4m net loss in 2 years). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€40.9m market cap, or US$45.8m).お知らせ • Jun 01Organoclick Launches Biobased and Eco-Labelled Textile WaterproofingAfter several years of research and development, OrganoClick is launching, within its brand OrganoTex, a newly developed and eco-labelled textile waterproofing with world-unique performance on the trade fair ISPO Outdoor 4-6 June in Munich. Through green chemistry that mimics nature's own water repellency, an excellent environmental profile and high technical performance are achieved. The products are biobased, biodegradable and eco-labelled and completely free of PFAS, fossil plastics, and synthetic waxes. The technology is based on combining the natural fatty acids of plants and the surface structure of leaves with the Nobel Prize-winning chemistry organocatalysis. The inspiration is the lotus leaf with its 3D structure and extreme water repellency. To succeed in this, the patented OrganoClick technology is used to "click" the natural fatty acids on the textile fibers. The result is a new generation of OrganoTex products that have improved water repellency and withstand morewashing cycles. The products are biobase and biodegradable, and contain neither PFAS, fossil-based plastics nor synthetic waxes. First out are the products OrganoTex Wash-In Textile Waterproofing and OrganoTex Spray-On Textile Waterproofing. Thanks to their excellent environmental profile, they have received the environmental label Oeko-Tex Eco Passport and USDA BioPreferred Certified Biobased Product. The products are also verified to be readily biodegradable according to the high requirements of the OECD 301F test. A world-unique product that both combines high performance and at the same time is biobased, plastic-free and biodegradable and, of course, PFAS-free. This innovation is fully in line with OrganoClick's overall mission to accelerate the phasing out of plastics and fossil chemicals towards overall vision of a nature free of plastics and toxic chemicals.お知らせ • May 19Organoclick AB (Publ) Announces Board ChangesOrganoClick AB (publ) at its Annual General Meeting on 17 May 2023 the company approved and elect Chatarina Schneider as board members. And Board also gave a big thank to the outgoing board member Claes-Göran Beckeman for his important contribution to the board and the company during his 15 years as a board member.Reported Earnings • Apr 09Full year 2022 earnings released: kr0.45 loss per share (vs kr0.34 loss in FY 2021)Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.34 loss in FY 2021). Revenue: kr115.0m (up 4.5% from FY 2021). Net loss: kr44.4m (loss widened 36% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.Recent Insider Transactions • Apr 08Chairman recently bought €18k worth of stockOn the 3rd of April, Jan Johansson bought around 50k shares on-market at roughly €0.36 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jan's only on-market trade for the last 12 months.Breakeven Date Change • Feb 17Forecast breakeven date pushed back to 2025The analyst covering OrganoClick previously expected the company to break even in 2024. New forecast suggests losses will reduce by 73% per year to 2024. The company is expected to make a profit of kr4.60m in 2025. Average annual earnings growth of 93% is required to achieve expected profit on schedule.お知らせ • Dec 12+ 5 more updatesOrganoClick AB (publ) to Report Q1, 2023 Results on May 05, 2023OrganoClick AB (publ) announced that they will report Q1, 2023 results on May 05, 2023Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Charlotte Jansdotter Karlberg was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Oct 08Forecast breakeven date pushed back to 2024The analyst covering OrganoClick previously expected the company to break even in 2023. New forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr12.0m in 2024. Average annual earnings growth of 98% is required to achieve expected profit on schedule.Reported Earnings • Aug 19Second quarter 2022 earnings released: kr0.09 loss per share (vs kr0.067 loss in 2Q 2021)Second quarter 2022 results: kr0.09 loss per share (down from kr0.067 loss in 2Q 2021). Revenue: kr38.5m (down 3.3% from 2Q 2021). Net loss: kr8.81m (loss widened 38% from 2Q 2021). Over the next year, revenue is forecast to grow 54%, compared to a 2.3% growth forecast for the Chemicals industry in Germany.Reported Earnings • May 05First quarter 2022 earnings released: kr0.06 loss per share (vs kr0.069 loss in 1Q 2021)First quarter 2022 results: kr0.06 loss per share (up from kr0.069 loss in 1Q 2021). Revenue: kr32.6m (up 10.0% from 1Q 2021). Net loss: kr5.89m (loss narrowed 6.8% from 1Q 2021). Over the next year, revenue is forecast to grow 59%, compared to a 8.5% growth forecast for the industry in Germany.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Charlotte Jansdotter Karlberg was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 09Full year 2021 earnings released: kr0.34 loss per share (vs kr0.26 loss in FY 2020)Full year 2021 results: kr0.34 loss per share (down from kr0.26 loss in FY 2020). Revenue: kr110.1m (up 14% from FY 2020). Net loss: kr32.7m (loss widened 38% from FY 2020). Over the next year, revenue is forecast to grow 52%, compared to a 9.6% growth forecast for the industry in Germany.お知らせ • Mar 29OrganoClick AB Appoints Mattias Bodin as New Environmental and Sustainability DirectorOrganoClick AB (publ) announced the appointment of Mattias Bodin as new Environmental and Sustainability Director at OrganoClick and part of Group management. Mattias has previously worked for almost 20 years within the HM Group, in positions such as Chemical responsible, Group manager HM Global product comliance department, Sustainability expert for Materials and Innovation most recently as HM Circular Innovation Lab Lead.Recent Insider Transactions • Feb 26Director recently bought €93k worth of stockOn the 23rd of February, Hakan Gustavson bought around 273k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €162k more in shares than they have sold in the last 12 months.Reported Earnings • Feb 19Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.34 loss per share (down from kr0.26 loss in FY 2020). Revenue: kr110.1m (up 14% from FY 2020). Net loss: kr32.7m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 55%, compared to a 6.6% growth forecast for the industry in Germany.Reported Earnings • Nov 17Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.072 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr22.6m (up 14% from 3Q 2020). Net loss: kr9.69m (loss widened 46% from 3Q 2020).Breakeven Date Change • Sep 23Forecast to breakeven in 2022The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr3.00m in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule.Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr39.8m (up 10% from 2Q 2020). Net loss: kr6.39m (loss widened 374% from 2Q 2020).Recent Insider Transactions • May 09Co-Founder recently bought €21k worth of stockOn the 5th of May, Marten Hellberg bought around 20k shares on-market at roughly €1.03 per share. This was the largest purchase by an insider in the last 3 months. Marten has been a buyer over the last 12 months, purchasing a net total of €24k worth in shares.Reported Earnings • May 06First quarter 2021 earnings released: kr0.069 loss per share (vs kr0.063 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr29.7m (up 33% from 1Q 2020). Net loss: kr6.33m (loss widened 8.8% from 1Q 2020).Reported Earnings • Apr 17Full year 2020 earnings released: kr0.26 loss per share (vs kr0.26 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr96.5m (up 13% from FY 2019). Net loss: kr23.6m (loss widened 16% from FY 2019).お知らせ • Feb 20OrganoClick Signs Agreement with Leading Nonwoven ManufacturerOrganoClick has signed a 5-year frame work agreement with a leading nonwoven manufacturer for supply of OrganoClick's biobased binders. The estimated value of the contract is around SEK 30 million per year when the biobinder has been fully implemented in the customers production. Under the 5-year term of the contract, OrganoClick will supply its biobinder according to a forecasted yearly volume that will be confirmed in detail in 6 month periods.During the coming six months (Q2-Q3) OrganoClick will gradually ramp up its production and supply to the customer and for this 6 month period, OrganoClick has received a confirmed order volume to a value of SEK 5 million. Full volume of the contract is expected to be reached in 2022.Reported Earnings • Feb 19Full year 2020 earnings released: kr0.26 loss per share (vs kr0.26 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr96.5m (up 13% from FY 2019). Net loss: kr23.6m (loss widened 16% from FY 2019).Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 54%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.収支内訳OrganoClick の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:0CF 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 2698-3537731 Dec 25106-3640630 Sep 25109-2637630 Jun 25116-2336631 Mar 25124-1937631 Dec 24127-1837630 Sep 24134-1837730 Jun 24138-1737731 Mar 24141-1737731 Dec 23146-1637730 Sep 23140-2839730 Jun 23128-3341731 Mar 23126-4042831 Dec 22115-4443830 Sep 22111-3642830 Jun 22112-3542831 Mar 22113-3241731 Dec 21110-3340830 Sep 21110-3138730 Jun 21108-2938731 Mar 21104-2434631 Dec 2096-2433530 Sep 2093-2331530 Jun 2089-2330531 Mar 2086-2330531 Dec 1985-2029430 Sep 1984-1829430 Jun 1984-1829431 Mar 1982-1830431 Dec 1878-2031330 Sep 1878-2332330 Jun 1878-2432431 Mar 1875-2631431 Dec 1775-2831430 Sep 1769-2634330 Jun 1762-2636231 Mar 1751-2838131 Dec 1640-2939030 Sep 1638-2837030 Jun 1637-2535031 Mar 1633-2233031 Dec 1532-2031030 Sep 1530-1728030 Jun 1527-16260質の高い収益: 0CFは現在利益が出ていません。利益率の向上: 0CFは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 0CFは利益を出していないが、過去 5 年間で年間5.8%の割合で損失を削減してきた。成長の加速: 0CFの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 0CFは利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -13.5% ) と比較することは困難です。株主資本利益率高いROE: 0CFは現在利益が出ていないため、自己資本利益率 ( -192.32% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:35終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋OrganoClick AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関null nullABG Sundal CollierJohan BrownABG Sundal Collier Sponsorednull nullABG Sundal Collier Sponsored1 その他のアナリストを表示
お知らせ • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026
お知らせ • Feb 13OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025
お知らせ • Dec 03+ 3 more updatesOrganoClick AB (publ) to Report Q1, 2025 Results on May 06, 2025OrganoClick AB (publ) announced that they will report Q1, 2025 results on May 06, 2025
Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.047 loss per share (vs kr0.042 loss in 3Q 2023)Third quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 22Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023)Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • May 02First quarter 2024 earnings released: kr0.022 loss per share (vs kr0.01 loss in 1Q 2023)First quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 24OrganoClick AB (publ), Annual General Meeting, May 26, 2026OrganoClick AB (publ), Annual General Meeting, May 26, 2026, at 16:00 W. Europe Standard Time. Location: organoclick`s head office at linjalvagen 9 in taby, Sweden
お知らせ • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026
お知らせ • Jul 18OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million.OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million. Security Name: Shares Security Type: Common Stock Securities Offered: 11,543,290 Price\Range: SEK 1.76 Transaction Features: Rights Offering
お知らせ • May 20OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) announced at the AGM held on May 20, 2025, approved Johan Magnusson was elected as Chairman of the Board. The Board also gave a big thank to the outgoing Chairman of the board Jan Johansson for his contribution to the board and the company during his 9 years as Chairman of the board.
お知らせ • Apr 16OrganoClick AB (publ), Annual General Meeting, May 20, 2025OrganoClick AB (publ), Annual General Meeting, May 20, 2025, at 13:00 W. Europe Standard Time. Location: at convendum, brahegatan 10, stockholm Sweden
お知らせ • Feb 13OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025
お知らせ • Dec 03+ 3 more updatesOrganoClick AB (publ) to Report Q1, 2025 Results on May 06, 2025OrganoClick AB (publ) announced that they will report Q1, 2025 results on May 06, 2025
Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.047 loss per share (vs kr0.042 loss in 3Q 2023)Third quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
New Risk • Nov 06New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (€24.4m market cap, or US$26.2m).
New Risk • Oct 29New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€25.0m market cap, or US$27.0m).
Reported Earnings • Jul 22Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023)Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Jun 15OrganoClick AB (publ) Announces CFO ChangesOrganoClick AB (publ) has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClick's finance and economics department and be part of the group's management team. Carin has more than 20 years of experience from various finance functions from, among others, Bristol Myers Squibb group, ByggFakta group and Team Olivia group. Carin has a M. Sc. in Economics with a specialization in financial mathematics at Karlstad University. For more than 25 years, Carin has worked in finance departments at both manufacturing companies and service companies, in both smaller companies and large groups. Previous experiences include roles as CFO for Olivia Hemomsorg, Finance manager for the medical technology company Convatec (part of the Bristol Myers Squibb Group), Head of Business Control Nordic region at ByggFakta Group and as Strategic Controller at the kitchen manufacturer Nobia. Carin takes over as CFO on July 15, and as previously announced, OrganoClick's current CFO Jessica Sundborg will leave the company 21 of August.
New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€27.7m market cap, or US$30.1m).
お知らせ • May 16OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) at its Annual General Meeting held on 15 May 2024 approved the election of Johan Magnusson as board member. The Board also gave a big thank to the outgoing board member Malin Bugge for her contribution to the board and the company during her 4 years as a board member.
Reported Earnings • May 02First quarter 2024 earnings released: kr0.022 loss per share (vs kr0.01 loss in 1Q 2023)First quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
New Risk • Apr 30New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (€25.4m market cap, or US$27.3m).
お知らせ • Apr 23OrganoWood AB (publ) Announces Three-Year Results from the Field Study EN 12037 for Organowood NowaOrganowood Nowa is currently subjected to one of the toughest standard field tests available for wood above ground, EN 12037! The test runs for 5 years in Malaysia and Denmark and now publish the three-year results. The independent external institute Dansk Teknologisk Institut therefore carries out the EN 12037 field test with Organowood Nowa in both Denmark and Malaysia. The references, which consist of untreated pine wood and the wood impregnated with CCA (chromium, copper and arenic), which has been banned for 20 years, were also included in the test. The scale for assessing degradation ranges from grade 0-4, where 0 meas that the wood is unaffected and 4 means that the wood is completely degraded. The untreated reference in Malaysia was completely degraded after 3 years, by rot fungus but also in some cases by termites. Pine pressure-impregnated with CCA was, as expected, unaffected. But also OrganoWood Nowa was completely unaffected with grade 0 on the scale! The result shows a very good wood protection even in the warm and humid environment that a rainforest offers. The field study will continue and will continuously report results from both Denmark and Malaysia.
お知らせ • Apr 19Jessica Sundborg to Leave as CFO of OrganoClick AB (publ)OrganoClick AB (publ) announced that its CFO since 2013, Jessica Sundborg is leaving her position to move on to a new position outside the company. Jessica will remain as CFO until she leaves her position after the summer. The work to recruit a successor has begun.
New Risk • Apr 17New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (€26.5m market cap, or US$28.2m).
お知らせ • Apr 11Organoclick AB (Publ) Announces That Malin Bugge, Board Member, Has Declined Re-ElectionOrganoClick AB (publ) announced that Malin Bugge, who has been a board member since 2020, has declined re-election.
Reported Earnings • Apr 08Full year 2023 earnings released: kr0.16 loss per share (vs kr0.45 loss in FY 2022)Full year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 23OrganoClick and PulPac Launches Plastic-Free Coffee Lid Reducing Co2 Footprint with 80%OrganoClick and PulPac has collaborated for several years in developing 100% biobased and biodegradable dry-molded products. By combining PulPac's dry molded fiber technology with OrganoClick's biobased and biodegradable binders, a biobased high-performing coffee lid, compliant with paper recycling have been developed. The innovative coffee lid is now launched for the take away market. PulPac's technology in combination with OrganoClick's biobased binders sets a new standard for high performing and sustainable packaging. It requires less energy and water than the traditional method, resulting in a reduced carbon footprint with up to 80% compared to traditional alternatives. One of the first products out is a plastic-free coffee lid which align with the recent EU legislation for take away product. Annual global consumption of coffee lids is estimated at 100,000,000,000 and with the new coffee lid, the CO2 footprint is reduced with up to 80%. The coffee lid is made green inside with the support of OrganoClick's biobased, biodegradable and home compostable binder, in part manufactured from waste streams from the food industry. The use of OrganoClick's binder resulting in a paper lid with much higher performance. The objectives are also to replace as much as possible of traditional plastic lids available on the market, thereby reducing the risk for microplastics ending up in the environment.
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.16 loss per share (vs kr0.45 loss in FY 2022)Full year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
お知らせ • Dec 20OrganoClick AB (publ), Annual General Meeting, May 15, 2024OrganoClick AB (publ), Annual General Meeting, May 15, 2024.
お知らせ • Dec 19+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 results on Feb 13, 2025
Reported Earnings • Nov 10Third quarter 2023 earnings released: kr0.042 loss per share (vs kr0.093 loss in 3Q 2022)Third quarter 2023 results: kr0.042 loss per share (improved from kr0.093 loss in 3Q 2022). Revenue: kr33.4m (up 50% from 3Q 2022). Net loss: kr4.13m (loss narrowed 55% from 3Q 2022). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany.
New Risk • Nov 10New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€26.4m market cap, or US$28.2m).
New Risk • Nov 04New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€28.3m market cap, or US$30.3m).
Breakeven Date Change • Nov 03Forecast to breakeven in 2025The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.90m in 2025. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
お知らせ • Oct 17OrganoClick AB (publ) Announces Nomination CommitteeOrganoClick AB (publ) announced composition of nomination committee. It is composed of Peter Lindell, representing Cidro Förvaltning and himself, Håkan Gustavson representing Beijer Ventures, the Beijer foundations, and himself, and Mårten Hellberg, representing M. Hellberg AB and himself. Peter Lindell was appointed as Chairman of the Nomination committee as the individually largest shareholder in OrganoClick AB.
Reported Earnings • Aug 18Second quarter 2023 earnings released: kr0.03 loss per share (vs kr0.09 loss in 2Q 2022)Second quarter 2023 results: kr0.03 loss per share (improved from kr0.09 loss in 2Q 2022). Revenue: kr41.0m (up 6.5% from 2Q 2022). Net loss: kr2.67m (loss narrowed 70% from 2Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.
New Risk • Jul 19New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr40m Forecast net loss in 2 years: kr1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr31m). Currently unprofitable and not forecast to become profitable over next 2 years (kr1.4m net loss in 2 years). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€40.9m market cap, or US$45.8m).
お知らせ • Jun 01Organoclick Launches Biobased and Eco-Labelled Textile WaterproofingAfter several years of research and development, OrganoClick is launching, within its brand OrganoTex, a newly developed and eco-labelled textile waterproofing with world-unique performance on the trade fair ISPO Outdoor 4-6 June in Munich. Through green chemistry that mimics nature's own water repellency, an excellent environmental profile and high technical performance are achieved. The products are biobased, biodegradable and eco-labelled and completely free of PFAS, fossil plastics, and synthetic waxes. The technology is based on combining the natural fatty acids of plants and the surface structure of leaves with the Nobel Prize-winning chemistry organocatalysis. The inspiration is the lotus leaf with its 3D structure and extreme water repellency. To succeed in this, the patented OrganoClick technology is used to "click" the natural fatty acids on the textile fibers. The result is a new generation of OrganoTex products that have improved water repellency and withstand morewashing cycles. The products are biobase and biodegradable, and contain neither PFAS, fossil-based plastics nor synthetic waxes. First out are the products OrganoTex Wash-In Textile Waterproofing and OrganoTex Spray-On Textile Waterproofing. Thanks to their excellent environmental profile, they have received the environmental label Oeko-Tex Eco Passport and USDA BioPreferred Certified Biobased Product. The products are also verified to be readily biodegradable according to the high requirements of the OECD 301F test. A world-unique product that both combines high performance and at the same time is biobased, plastic-free and biodegradable and, of course, PFAS-free. This innovation is fully in line with OrganoClick's overall mission to accelerate the phasing out of plastics and fossil chemicals towards overall vision of a nature free of plastics and toxic chemicals.
お知らせ • May 19Organoclick AB (Publ) Announces Board ChangesOrganoClick AB (publ) at its Annual General Meeting on 17 May 2023 the company approved and elect Chatarina Schneider as board members. And Board also gave a big thank to the outgoing board member Claes-Göran Beckeman for his important contribution to the board and the company during his 15 years as a board member.
Reported Earnings • Apr 09Full year 2022 earnings released: kr0.45 loss per share (vs kr0.34 loss in FY 2021)Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.34 loss in FY 2021). Revenue: kr115.0m (up 4.5% from FY 2021). Net loss: kr44.4m (loss widened 36% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.
Recent Insider Transactions • Apr 08Chairman recently bought €18k worth of stockOn the 3rd of April, Jan Johansson bought around 50k shares on-market at roughly €0.36 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jan's only on-market trade for the last 12 months.
Breakeven Date Change • Feb 17Forecast breakeven date pushed back to 2025The analyst covering OrganoClick previously expected the company to break even in 2024. New forecast suggests losses will reduce by 73% per year to 2024. The company is expected to make a profit of kr4.60m in 2025. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
お知らせ • Dec 12+ 5 more updatesOrganoClick AB (publ) to Report Q1, 2023 Results on May 05, 2023OrganoClick AB (publ) announced that they will report Q1, 2023 results on May 05, 2023
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Charlotte Jansdotter Karlberg was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Oct 08Forecast breakeven date pushed back to 2024The analyst covering OrganoClick previously expected the company to break even in 2023. New forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr12.0m in 2024. Average annual earnings growth of 98% is required to achieve expected profit on schedule.
Reported Earnings • Aug 19Second quarter 2022 earnings released: kr0.09 loss per share (vs kr0.067 loss in 2Q 2021)Second quarter 2022 results: kr0.09 loss per share (down from kr0.067 loss in 2Q 2021). Revenue: kr38.5m (down 3.3% from 2Q 2021). Net loss: kr8.81m (loss widened 38% from 2Q 2021). Over the next year, revenue is forecast to grow 54%, compared to a 2.3% growth forecast for the Chemicals industry in Germany.
Reported Earnings • May 05First quarter 2022 earnings released: kr0.06 loss per share (vs kr0.069 loss in 1Q 2021)First quarter 2022 results: kr0.06 loss per share (up from kr0.069 loss in 1Q 2021). Revenue: kr32.6m (up 10.0% from 1Q 2021). Net loss: kr5.89m (loss narrowed 6.8% from 1Q 2021). Over the next year, revenue is forecast to grow 59%, compared to a 8.5% growth forecast for the industry in Germany.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Charlotte Jansdotter Karlberg was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 09Full year 2021 earnings released: kr0.34 loss per share (vs kr0.26 loss in FY 2020)Full year 2021 results: kr0.34 loss per share (down from kr0.26 loss in FY 2020). Revenue: kr110.1m (up 14% from FY 2020). Net loss: kr32.7m (loss widened 38% from FY 2020). Over the next year, revenue is forecast to grow 52%, compared to a 9.6% growth forecast for the industry in Germany.
お知らせ • Mar 29OrganoClick AB Appoints Mattias Bodin as New Environmental and Sustainability DirectorOrganoClick AB (publ) announced the appointment of Mattias Bodin as new Environmental and Sustainability Director at OrganoClick and part of Group management. Mattias has previously worked for almost 20 years within the HM Group, in positions such as Chemical responsible, Group manager HM Global product comliance department, Sustainability expert for Materials and Innovation most recently as HM Circular Innovation Lab Lead.
Recent Insider Transactions • Feb 26Director recently bought €93k worth of stockOn the 23rd of February, Hakan Gustavson bought around 273k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €162k more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 19Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.34 loss per share (down from kr0.26 loss in FY 2020). Revenue: kr110.1m (up 14% from FY 2020). Net loss: kr32.7m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 55%, compared to a 6.6% growth forecast for the industry in Germany.
Reported Earnings • Nov 17Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.072 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr22.6m (up 14% from 3Q 2020). Net loss: kr9.69m (loss widened 46% from 3Q 2020).
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr3.00m in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr39.8m (up 10% from 2Q 2020). Net loss: kr6.39m (loss widened 374% from 2Q 2020).
Recent Insider Transactions • May 09Co-Founder recently bought €21k worth of stockOn the 5th of May, Marten Hellberg bought around 20k shares on-market at roughly €1.03 per share. This was the largest purchase by an insider in the last 3 months. Marten has been a buyer over the last 12 months, purchasing a net total of €24k worth in shares.
Reported Earnings • May 06First quarter 2021 earnings released: kr0.069 loss per share (vs kr0.063 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr29.7m (up 33% from 1Q 2020). Net loss: kr6.33m (loss widened 8.8% from 1Q 2020).
Reported Earnings • Apr 17Full year 2020 earnings released: kr0.26 loss per share (vs kr0.26 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr96.5m (up 13% from FY 2019). Net loss: kr23.6m (loss widened 16% from FY 2019).
お知らせ • Feb 20OrganoClick Signs Agreement with Leading Nonwoven ManufacturerOrganoClick has signed a 5-year frame work agreement with a leading nonwoven manufacturer for supply of OrganoClick's biobased binders. The estimated value of the contract is around SEK 30 million per year when the biobinder has been fully implemented in the customers production. Under the 5-year term of the contract, OrganoClick will supply its biobinder according to a forecasted yearly volume that will be confirmed in detail in 6 month periods.During the coming six months (Q2-Q3) OrganoClick will gradually ramp up its production and supply to the customer and for this 6 month period, OrganoClick has received a confirmed order volume to a value of SEK 5 million. Full volume of the contract is expected to be reached in 2022.
Reported Earnings • Feb 19Full year 2020 earnings released: kr0.26 loss per share (vs kr0.26 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr96.5m (up 13% from FY 2019). Net loss: kr23.6m (loss widened 16% from FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 54%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.